A recent study has found a potential link between weight-loss injections and an increased risk of developing an eye condition that could lead to blindness. The study focused on patients who were prescribed semaglutide, which is commonly known as Wegovy and Ozempic.
The research, conducted by Harvard University and published in JAMA Ophthalmology, analyzed data from 16,827 patients at the Mass Eye and Ear Harvard teaching hospital over a six-year period. The study revealed that individuals with diabetes who were prescribed semaglutide were more than four times more likely to be diagnosed with a condition called non-arteritic anterior ischemic optic neuropathy (naion).
Naion is a disorder where the arteries that supply blood to the optic nerve in the eye become blocked, leading to a loss of eyesight. Unfortunately, there is currently no known treatment for this condition, which affects a small percentage of the general population.
Of the patients included in the study, 710 had type 2 diabetes, with 194 of them being prescribed semaglutide. Additionally, 975 patients were overweight or obese, with 361 of them receiving semaglutide for weight loss.
The results showed that individuals with type 2 diabetes who were prescribed semaglutide had a higher incidence of naion compared to those on other diabetes medications. Similarly, patients who were overweight or obese and taking semaglutide were also at a greater risk of developing the condition compared to those on other weight-loss drugs.
While the findings are significant, the researchers emphasize the need for larger and more diverse studies to further explore these associations. Patients who are considering or currently taking semaglutide should discuss the potential risks with their healthcare providers, especially if they have existing optic nerve issues like glaucoma.
Experts in the field suggest that more research is needed to fully understand the relationship between semaglutide treatment and sight-threatening optic neuropathy. As the use of semaglutide continues to rise, particularly for conditions beyond obesity and type 2 diabetes, it is essential to weigh the possible side effects against the anticipated benefits.
It is important to note that semaglutide, under the brand name Wegovy, has been prescribed for weight loss in the NHS since 2023. The manufacturer of Ozempic and Wegovy, Novo Nordisk, prioritizes patient safety and takes all reports of adverse events seriously. While non-arteritic anterior ischemic optic neuropathy is not currently listed as a known adverse reaction to semaglutide, ongoing monitoring and research are essential to ensure patient well-being.
